

07 Aug 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie's Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 August 2022, including: planned US drug pricing legislation in focus; solid quarter but no [\*Seagen Inc.\*](#) announcement for [\*Merck & Co., Inc.\*](#); [\*AbbVie Inc.\*](#)'s Gonzalez sounds alarm over US pricing legislation; [\*Alnylam Pharmaceuticals Inc.\*](#) ready to expand in amyloidosis; and [\*Boehringer Ingelheim GmbH\*](#) on global Jardiance strategy.

This and all our other podcasts are available on the Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Pharma Braces For Potential Landmark Moment For US Drug Price Controls\*](#)" - Scrip, 2 Aug, 2022.)

(Also see "[\*Merck's Solid Quarter Doesn't Soothe Seagen M&A Watchers\*](#)" - Scrip, 28 Jul, 2022.)

(Also see "[\*AbbVie's Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal\*](#)" - Scrip, 29 Jul, 2022.)

(Also see "[\*Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results\*](#)" - Scrip, 3 Aug, 2022.)

(Also see "[\*Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye\*](#)" - Scrip, 2 Aug, 2022.)

[Click here to explore this interactive content online](#) ✎